Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Releases

  • Webcast Image Webcast
    Spring Bank Pharmaceuticals Top-Line Results of Second Cohort (50mg) of Part A of Phase 2 ACHIEVE Trial  (Replay)
    Thursday, November 16, 2017 8:00 am EST
Toggle Summary Spring Bank Pharmaceuticals Announces Positive Top-Line Results from the Second Cohort of Part A of the Phase 2 ACHIEVE Trial
Low Dose of Inarigivir Soproxil (50mg) Monotherapy Demonstrates a Favorable Safety Profile and Significant Dose-Dependent Antiviral Activity, Meeting Both Primary Endpoints Conference Call Scheduled for Tomorrow, Nov. 16 at 8:00 a.m. EST HOPKINTON, Mass. , Nov.
Toggle Summary Spring Bank to Present at Piper Jaffray’s 29th Annual Healthcare Conference
HOPKINTON, Mass. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin J.
Toggle Summary Spring Bank Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial and Operational Results
Quarter highlighted by data presentations at two conferences and the initiation of research collaborations Confirms top-line results from the second inarigivir (formerly SB 9200) monotherapy dosing cohort of the ACHIEVE trial will be released in Q4 2017 HOPKINTON, Mass. , Oct.
Toggle Summary Spring Bank Pharmaceuticals Announces Additional Inarigivir (formerly SB 9200) Results from the ACHIEVE Trial in HBV Patients at AASLD Conference
Inarigivir Phase 2 results confirm antiviral activity & novel mechanism of action Data Safety Monitoring Board approves proceeding with enrollment of third cohort (inarigivir 100mg) of the ACHIEVE trial HOPKINTON, Mass. , Oct. 20, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc.
Toggle Summary Spring Bank Pharmaceuticals Announces Two Presentations at the 2017 AASLD Conference in Washington, D.C.
HOPKINTON, Mass. , Oct. 06, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced two presentations at the
Toggle Summary Spring Bank Pharmaceuticals Announces Presentation of Positive Preclinical Data on SB 11285 at the 2017 AACR Conference on Tumor Immunology and Immunotherapy
SB 11285 Shows Potent and Highly-Durable Anti-Tumor Activity in Several Tumor Models HOPKINTON, Mass. , Oct. 02, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections,
Toggle Summary Spring Bank Pharmaceuticals Announces a Poster Presentation of its lead STING Agonist, SB 11285, at the 2017 AACR Conference on Tumor Immunology and Immunotherapy in Boston, MA
Data to highlight recent preclinical studies of SB 11285, a novel next-generation STING agonist HOPKINTON, Mass. , Sept. 19, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral
Toggle Summary Spring Bank to Present at the Cantor Fitzgerald Global Healthcare Conference
HOPKINTON, Mass. , Sept. 13, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin J.
Toggle Summary Spring Bank to Present Additional Data from the First Cohort of its Ongoing SB 9200 ACHIEVE Clinical Trial at the 2017 International HBV Meeting in Washington D.C.
HOPKINTON, Mass. , Aug. 28, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that a scientific abstract
Toggle Summary Spring Bank Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial and Operational Results
Reports multiple recent developments and milestones Plans to report top-line results from the second monotherapy dosing cohort of the ACHIEVE global Phase 2 clinical trial of SB 9200 in chronic HBV in 4Q 2017 Successful $40 million equity financing expected to fund company through end of 2019